Antiplatelet therapy: current strategies and future trends.


Journal Article

Pharmacological management of thrombotic complications is strongly influenced by antiplatelet treatment strategies. Recent clinical trials have clearly indicated that current antiplatelet strategies may not inhibit recurrent thrombotic events in selected patients and improvement is necessary. Recently, there has been a gradual modification in the guidelines for clopidogrel dosing. In addition, newly developed P2Y(12) receptor inhibitors and thrombin inhibitors are undergoing Phase II and III clinical trials. Moreover, research related to novel agents that interfere with other steps in coagulation and platelet adhesion, and platelet thromboxane and thrombin receptor blockers, show promise. An important future step will probably be the development of personalized therapy based on defining the individual patient's propensity for thrombosis through investigation of platelet-thrombin-fibrin interactions. Such an approach will enhance the targeting of specific therapy based on the pathophysiology of the individual patient.

Full Text

Duke Authors

Cited Authors

  • Tantry, US; Etherington, A; Bliden, KP; Gurbel, PA

Published Date

  • May 2006

Published In

Volume / Issue

  • 2 / 3

Start / End Page

  • 343 - 366

PubMed ID

  • 19804092

Pubmed Central ID

  • 19804092

Electronic International Standard Serial Number (EISSN)

  • 1744-8298

Digital Object Identifier (DOI)

  • 10.2217/14796678.2.3.343


  • eng

Conference Location

  • England